Journal of Movement Disorders

Ju-Hee Kang

2 Articles

MicroRNA Biomarkers in Neurodegenerative Diseases and Emerging NanoSensors Technology: Pratik Shah, Seok Keun Cho, Peter Waaben Thulstrup, Morten Jannik Bjerrum, Phil Hyu Lee, Ju-Hee Kang, Yong-Joo Bhang, Seong Wook Yang; J Mov Disord. 2017;10(1):18-28. Published online January 18, 2017; DOI: https://doi.org/10.14802/jmd.16037

16,968 View
379 Download
24 Web of Science
20 Crossref

MicroRNAs (miRNAs) are essential small RNA molecules (20–24 nt) that negatively regulate the expression of target genes at the post-transcriptional level. Due to their roles in a variety of biological processes, the aberrant expression profiles of miRNAs have been identified as biomarkers for many diseases, such as cancer, diabetes, cardiovascular disease and neurodegenerative diseases. In order to precisely, rapidly and economically monitor the expression of miRNAs, many cutting-edge nanotechnologies have been developed. One of the nanotechnologies, based on DNA encapsulated silver nanoclusters (DNA/AgNCs), has increasingly been adopted to create nanoscale bio-sensing systems due to its attractive optical properties, such as brightness, tuneable emission wavelengths and photostability. Using the DNA/AgNCs sensor methods, the presence of miRNAs can be detected simply by monitoring the fluorescence alteration of DNA/AgNCs sensors. We introduce these DNA/ AgNCs sensor methods and discuss their possible applications for detecting miRNA biomarkers in neurodegenerative diseases.

Citations

Citations to this article as recorded by

Nanosensors for the diagnosis and therapy of neurodegenerative disorders and inflammatory bowel disease
Thirunavukkarsu Palaniyandi, Kanagavalli B, Pranav Prabhakaran, Sandhiya Viswanathan, Mugip Rahaman Abdul Wahab, Sudhakar Natarajan, Senthil Kumar Kaliya Moorthy, Saravanan Kumarasamy
Acta Histochemica.2023; 125(2): 151997. CrossRef
Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics
Kaifee Arman, Zeinab Dalloul, Esra Bozgeyik
Gene.2023; 861: 147232. CrossRef
Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications
Daniel Sanchez-Tejerina, Arnau Llaurado, Javier Sotoca, Veronica Lopez-Diego, Jose M. Vidal Taboada, Maria Salvado, Raul Juntas-Morales
Cells.2023; 12(8): 1180. CrossRef
Rapid detection of SARS-CoV-2 genetic targets using nanoporous waveguide based competitive displacement assay
Megan Makela, Zhihai Lin, Pao Tai Lin
Giant.2023; 15: 100173. CrossRef
Micro Nanoengraving Technology and Aesthetic Practice of Architectural Sculpture Art
Weili Zhu, Dong Wei, Awais Ahmed
Journal of Nanomaterials.2022; 2022: 1. CrossRef
Morphine-mediated release of astrocyte-derived extracellular vesicle miR-23a induces loss of pericyte coverage at the blood-brain barrier: Implications for neuroinflammation
Ke Liao, Fang Niu, Guoku Hu, Shilpa Buch
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
A Review on the Role of Nanosensors in Detecting Cellular miRNA Expression in Colorectal Cancer
Koyeli Girigoswami, Agnishwar Girigoswami
Endocrine, Metabolic & Immune Disorders - Drug Targets.2021; 21(1): 12. CrossRef
Duplex DNA-functionalized graphene oxide: A versatile platform for miRNA sensing
Bomi Shin, Woo-Keun Kim, Seokjoo Yoon, Jieon Lee
Sensors and Actuators B: Chemical.2020; 305: 127471. CrossRef
Recent advances in the bioanalytical and biomedical applications of DNA-templated silver nanoclusters
Jiaqi Xu, Xuanmeng Zhu, Xi Zhou, Farjana Yeasmin Khusbu, Changbei Ma
TrAC Trends in Analytical Chemistry.2020; 124: 115786. CrossRef
Identification of Ovine Serum miRNAs Following Bacterial Lipopolysaccharide Challenge
Ankita Sharma, Umesh K. Shandilya, Tianna Sullivan, Danielle Naylor, Angela Canovas, Bonnie A. Mallard, Niel A. Karrow
International Journal of Molecular Sciences.2020; 21(21): 7920. CrossRef
Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease
Seth A. Bennett, Royena Tanaz, Samantha N. Cobos, Mariana P. Torrente
Translational Research.2019; 204: 19. CrossRef
Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer’s disease
Md. Rezanur Rahman, Tania Islam, Beste Turanli, Toyfiquz Zaman, Hossain Md. Faruquee, Md. Mafizur Rahman, Md. Nurul Haque Mollah, Ranjan Kumar Nanda, Kazim Yalcin Arga, Esra Gov, Mohammad Ali Moni
Computational Biology and Chemistry.2019; 78: 431. CrossRef
Generic Neutravidin Biosensor for Simultaneous Multiplex Detection of MicroRNAs via Electrochemically Encoded Responsive Nanolabels
Sawsen Azzouzi, Zina Fredj, Anthony P. F. Turner, Mounir Ben Ali, Wing Cheung Mak
ACS Sensors.2019; 4(2): 326. CrossRef
MiR‐140 modulates the inflammatory responses of Mycobacterium tuberculosis‐infected macrophages by targeting TRAF6
Xiaofei Li, Shan Huang, Tingting Yu, Guiliang Liang, Hongwei Liu, Dong Pu, Niancai Peng
Journal of Cellular and Molecular Medicine.2019; 23(8): 5642. CrossRef
Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases
Eugene M. Cilento, Lorrain Jin, Tessandra Stewart, Min Shi, Lifu Sheng, Jing Zhang
Journal of Neurochemistry.2019; 151(4): 397. CrossRef
MicroRNA Assisted Gene Regulation in Colorectal Cancer
Adewale Fadaka, Ashley Pretorius, Ashwil Klein
International Journal of Molecular Sciences.2019; 20(19): 4899. CrossRef
Circulating miRNAs, Small but Promising Biomarkers for Autism Spectrum Disorder
Salam Salloum-Asfar, Noothan J. Satheesh, Sara A. Abdulla
Frontiers in Molecular Neuroscience.2019;[Epub] CrossRef
A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s disease
Zahra Aghili, Navid Nasirizadeh, Adeleh Divsalar, Shahram Shoeibi, Parichehreh Yaghmaei
Artificial Cells, Nanomedicine, and Biotechnology.2018; 46(sup1): 32. CrossRef
Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays
Augusto M. Tentori, Maxwell B. Nagarajan, Jae Jung Kim, Wen Cai Zhang, Frank J. Slack, Patrick S. Doyle
Lab on a Chip.2018; 18(16): 2410. CrossRef
The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis
Efthimios Dardiotis, Athina-Maria Aloizou, Vasileios Siokas, George P. Patrinos, Georgia Deretzi, Panayiotis Mitsias, Michael Aschner, Aristidis Tsatsakis
Journal of Molecular Neuroscience.2018; 66(4): 617. CrossRef

Cerebrospinal Fluid Amyloid β_1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease: Ju-Hee Kang; J Mov Disord. 2016;9(2):89-96. Published online May 25, 2016; DOI: https://doi.org/10.14802/jmd.16017

20,120 View
243 Download
18 Web of Science
18 Crossref

Abstract PDF

Parkinson’s disease (PD) is a neurodegenerative disease with heterogeneous pathological and clinical features. Cognitive dysfunction, a frequent non-motor complication, is a risk factor for poor prognosis and shows inter-individual variation in its progression. Of the clinical studies performed to identify biomarkers of PD progression, the Parkinson’s Progression Markers Initiative (PPMI) study is the largest study that enrolled drug-naïve and very early stage PD patients. The baseline characteristics of the PPMI cohort were recently published. The diagnostic utility of cerebrospinal fluid (CSF) biomarkers, including alpha-synuclein (α-syn), total tau, phosphorylated tau at Thr₁₈₁, and amyloid β_1-42, was not satisfactory. However, the baseline data on CSF biomarkers in the PPMI study suggested that the measurement of the CSF biomarkers enables the prediction of future cognitive decline in PD patients, which was consistent with previous studies. To prove the hypothesis that the interaction between Alzheimer’s pathology and α-syn pathology is important to the progression of cognitive dysfunction in PD, longitudinal observational studies must be followed. In this review, the neuropathological nature of heterogeneous cognitive decline in PD is briefly discussed, followed by a summarized interpretation of baseline CSF biomarkers derived from the data in the PPMI study. The combination of clinical, biochemical, genetic and imaging biomarkers of PD constitutes a feasible strategy to predict the heterogeneous progression of PD.

Citations

Citations to this article as recorded by

Highly sensitive biosensor based on IGZO thin-film transistors for detection of Parkinson's disease
Tongzheng Li, Tongying Xu, Zhengyang Yao, Yanan Ding, Guoxia Liu, Fukai Shan
Applied Physics Letters.2023;[Epub] CrossRef
Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease
Joseph Blommer, Toni Pitcher, Maja Mustapic, Erden Eren, Pamela J Yao, Michael P Vreones, Krishna A Pucha, John Dalrymple-Alford, Reza Shoorangiz, Wassilios G Meissner, Tim Anderson, Dimitrios Kapogiannis
Brain.2023; 146(1): 195. CrossRef
Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
John P. Seibyl
Journal of Nuclear Medicine.2023; 64(1): 12. CrossRef
REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study
Fardin Nabizadeh, Kasra Pirahesh, Parya Valizadeh
Journal of Neurology.2022; 269(9): 4836. CrossRef
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
Thomas Kremer, Kirsten I. Taylor, Juliane Siebourg‐Polster, Thomas Gerken, Andreas Staempfli, Christian Czech, Juergen Dukart, Douglas Galasko, Tatiana Foroud, Lana M. Chahine, Christopher S. Coffey, Tanya Simuni, Daniel Weintraub, John Seibyl, Kathleen L
Movement Disorders.2021; 36(8): 1972. CrossRef
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis
J. M. Hatcher-Martin, J. L. McKay, A. F. Pybus, B. Sommerfeld, J. C. Howell, F. C. Goldstein, L. Wood, W. T. Hu, S. A. Factor
npj Parkinson's Disease.2021;[Epub] CrossRef
Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model
Mehmet Ozansoy, Muzaffer Beyza Ozansoy, Burak Yulug, Seyda Cankaya, Ertugrul Kilic, Sule Goktekin, Ulkan Kilic
Journal of Clinical Neuroscience.2020; 73: 237. CrossRef
Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology
Maja Malmberg, Tarja Malm, Oskar Gustafsson, Andrea Sturchio, Caroline Graff, Alberto J. Espay, Anthony P. Wright, Samir El Andaloussi, Anders Lindén, Kariem Ezzat
Frontiers in Neuroscience.2020;[Epub] CrossRef
Why would Parkinson’s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses
Jon O. Lauring, Tomohiro Ishizu, Hana H. Kutlikova, Felix Dörflinger, Steven Haugbøl, Helmut Leder, Ron Kupers, Matthew Pelowski
Neuroscience & Biobehavioral Reviews.2019; 100: 129. CrossRef
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
Tracy R. Melzer, Megan R. Stark, Ross J. Keenan, Daniel J. Myall, Michael R. MacAskill, Toni L. Pitcher, Leslie Livingston, Sophie Grenfell, Kyla-Louise Horne, Bob N. Young, Maddie J. Pascoe, Mustafa M. Almuqbel, Jian Wang, Steven H. Marsh, David H. Mille
Frontiers in Neurology.2019;[Epub] CrossRef
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Kurt A. Jellinger
Journal of Neural Transmission.2018; 125(4): 615. CrossRef
Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study
George D. Vavougios, Triantafyllos Doskas, Constantinos Kormas, Karen A. Krogfelt, Sotirios G. Zarogiannis, Leonidas Stefanis
Journal of the Neurological Sciences.2018; 387: 103. CrossRef
Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease
Nooshin Abbasi, Bahram Mohajer, Sima Abbasi, Payam Hasanabadi, Amirhussein Abdolalizadeh, Reza Rajimehr
Movement Disorders.2018; 33(3): 431. CrossRef
Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
Mahsa Dolatshahi, Shayan Pourmirbabaei, Aida Kamalian, Amir Ashraf-Ganjouei, Mehdi Yaseri, Mohammad H. Aarabi
Frontiers in Neurology.2018;[Epub] CrossRef
Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study
Manuel Delgado‐Alvarado, Rosalía Dacosta‐Aguayo, Irene Navalpotro‐Gómez, Belén Gago, Ana Gorostidi, Haritz Jiménez‐Urbieta, Ana Quiroga‐Varela, Javier Ruiz‐Martínez, Alberto Bergareche, María C. Rodríguez‐Oroz
Movement Disorders.2018; 33(11): 1809. CrossRef
Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases
Ji-Young Choi, Sujin Kim, Hyo-Bum Kwak, Dong-Ho Park, Jae-Hyoung Park, Jeong-Seon Ryu, Chang-Shin Park, Ju-Hee Kang
International Neurourology Journal.2017; 21(2): 83. CrossRef
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum, Jianjun Chang, Jaegwon Chung, Chelsea Caspell-Garcia, Peggy Taylor, Brit Mollenhauer, Michael G. Schlossmacher, Larry Ereshefsky, Mark Yen, Catherine Kopil, Mark Frasier, Kenneth Marek, Vicki S.
Journal of Neuroinflammation.2017;[Epub] CrossRef
Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias
Julie A Fields
Archives of Clinical Neuropsychology.2017; 32(7): 786. CrossRef

Author index